Carmell Therapeutics Named Pittsburgh Tech 50 Awards Finalist
October 12, 2017
Pittsburgh Technology Council Names Category Leaders on October 12, 2017
PITTSBURGH, PA – Carmell Therapeutics, a privately-owned biotechnology company focused on the development and commercialization of innovative Plasma-based Bioactive Materials (PBMs), today announced that the Pittsburgh Technology Council has named it a Tech 50 Category Leader in the Innovator of the Year: Life Sciences Category.
The Pittsburgh Technology Council’s annual Tech 50 Awards recognize southwestern Pennsylvania’s most successful, innovative, and thought-leading technology companies, which have become the backbone of Pittsburgh’s innovation economy. The awards represent transformative technology centers of excellence with tech companies at all stages of growth. Tech 50 also recognizes the region’s top tech executive.
"Each year, the Council canvasses the region for the most distinguished public and private technology-oriented companies, and the Tech 50 awards honor those companies that demonstrated the strongest growth and advancement in product or sales success, corporate citizenship, job growth and retention, industry achievement and innovative product or technology,” said Audrey Russo, President and CEO, Pittsburgh Technology Council. “We are especially excited to announce the category winners at the awards gala this fall. This year, we are taking a closer look at how the finalists are propelling technology excellence not only in Pittsburgh, but around the world. It is truly a night to honor our region’s technology companies and the contributions they have made to our economic vitality.”
Randy Hubbell, President and CEO of Carmell Therapeutics, stated, “Carmell Therapeutics is a regenerative medicine company focused on enhancing and accelerating the healing process for both, bone and soft tissue. Our biggest accomplishments have been a meeting with the FDA where they have agreed that Carmell is ready to move to Phase III clinical development for its first product, Bone Healing Accelerant. In addition to that, we moved into a new facility, a manufacturing suite that is now ISO 7 certified, that is allowing us to continue our success and progress on our journey to creating a regenerative medicine company.”
For further information on Carmell Therapeutics and its solutions please visit Carmellrx.com